Showing 1 to 2 of 2 results


BioNTech to Acquire CureVac, Boosting Tübingen's Biotech Hub
BioNTech, a Mainz-based pharmaceutical company, plans to acquire its Tübingen-based rival CureVac in a multi-billion euro deal, aiming to expand mRNA-based cancer immunotherapy research and development in Tübingen, strengthening the region's biotech hub and securing high-skilled jobs.
BioNTech to Acquire CureVac, Boosting Tübingen's Biotech Hub
BioNTech, a Mainz-based pharmaceutical company, plans to acquire its Tübingen-based rival CureVac in a multi-billion euro deal, aiming to expand mRNA-based cancer immunotherapy research and development in Tübingen, strengthening the region's biotech hub and securing high-skilled jobs.
Progress
44% Bias Score

BioNTech to Acquire Curevac for $1.25 Billion
BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.

BioNTech to Acquire Curevac for $1.25 Billion
BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.
Progress
32% Bias Score
Showing 1 to 2 of 2 results